Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Code of Conduct [a]
CC transcript
EyePoint Pharmaceuticals, Inc. (EYPT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/24/2023 4 EW Healthcare Partners, L.P. (10% Owner) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.
Txns: Sold 46,778 shares @ $14.6187, valued at $683.8k
Sold 121,103 shares @ $13.0543, valued at $1.6M
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/04/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/02/2023 8-K Quarterly results
07/27/2023 8-K Investor presentation
Docs: "EyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation Summit - Interim safety data from the Phase 2 DAVIO 2 trial continues to demonstrate EYP-1901 is well tolerated with no reported drug-related ocular or systemic SAEs - - Patient demographics demonstrate the Phase 2 DAVIO 2 population has a better baseline BCVA and decreased CST compared to the Phase 1 DAVIO trial cohort at trial start- - Phase 2 DAVIO 2 clinical trial remains on track to report topline data in December 2023 - WATERTOWN, Mass., July 27, 2023 – EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced interim m...",
"EYP-1901 PHASE 1 DAVIO CLINICAL"
07/12/2023 4 Duker Jay S. (President and CEO) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.
Txns: Granted 50,000 restricted stock units @ $0
Granted 100,000 options to buy @ $9.11, valued at $911k
07/12/2023 4 Lurker Nancy (Executive Vice Chair) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.
Txns: Granted 33,334 restricted stock units @ $0
Granted 66,666 options to buy @ $9.11, valued at $607.3k
07/12/2023 4 Zaderej Karen L. (Director) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.
Txns: Exercised 2,000 restricted stock units @ $0
07/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "VOROLANIB VOROLANIB VOROLANIB VEGF-A VEGF-B VEGF-C VEGF-D R1"
07/10/2023 8-K Quarterly results
05/31/2023 4 Liu Ye (Director) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.
Txns: Sold 1 shares @ $6, valued at $6
05/30/2023 4 Pine Michael Craig (Chief Corp Dev.&Strat. Officer) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.
Txns: Granted 15,000 options to buy @ $5.93, valued at $89k
Granted 7,500 restricted stock units @ $0
05/30/2023 4 Elston George (CFO) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.
Txns: Granted 45,000 options to buy @ $5.93, valued at $266.9k
Granted 22,500 restricted stock units @ $0
05/26/2023 144/A Form 144/A - Report of proposed sale of securities: [Amend]
05/26/2023 144/A Form 144/A - Report of proposed sale of securities: [Amend]
05/26/2023 144 Form 144 - Report of proposed sale of securities:
05/23/2023 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "Unaudited Pro Forma Financial Statements and accompanying notes"
05/18/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
Docs: "PRODUCT RIGHTS AGREEMENT between EyePoint Pharmaceuticals, Inc. and Alimera Sciences, Inc.",
"COMMERCIAL SUPPLY AGREEMENT This COMMERCIAL SUPPLY AGREEMENT is made as of May 17, 2023 , by and between EyePoint Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 480 Pleasant Street, Suite C-400, Watertown, MA 02472 , and Alimera Sciences, Inc., a Delaware corporation with its principal place of business at 6310 Town Square, Suite 400, Alpharetta, GA 30005 . Capitalized terms used, but not otherwise defined, in this Agreement have the meanings assigned to them in the Product Rights Agreement . RECITALS Whereas, EyePoint owns the rights to, and has commercialized in the United States, YUTIQ® 0.18 mg , which was approved by the U.S. Food and Drug Administration for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye...",
"EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties –$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024 – All outstanding bank debt retired and expected cash runway extended into 2025 – EyePoint well-capitalized beyond key EYP-1901 Phase 2 DAVIO 2 and PAVIA clinical trial inflection points WATERTOWN, Mass., May 18, 2023 – EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that it has entered into a definitive agreement for the sale of YUTIQ® 0.18mg to Alimera Sciences, Inc. . YUTIQ is a treatment for chronic non-infectious uveitis affecting the posterior segment ..."
05/15/2023 4 Lurker Nancy (CEO) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.
Txns: Gifted 21,250 options to buy @ $36.3, valued at $771.4k
Gifted 21,250 options to buy @ $36.3, valued at $771.4k
Gifted 65,868 options to buy @ $26.5, valued at $1.7M
Gifted 65,868 options to buy @ $26.5, valued at $1.7M
Gifted 36,000 options to buy @ $20.4, valued at $734.4k
Gifted 36,000 options to buy @ $20.4, valued at $734.4k
Gifted 8,000 options to buy @ $17.7, valued at $141.6k
Gifted 8,000 options to buy @ $17.7, valued at $141.6k
Gifted 120,206 options to buy @ $13.13, valued at $1.6M
Gifted 120,206 options to buy @ $13.13, valued at $1.6M
Gifted 59,220 options to buy @ $12.9, valued at $763.9k
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/03/2023 8-K Quarterly results
05/01/2023 SC 13G/A Cormorant Global Healthcare Master Fund, LP reports a 9.3% stake in EyePoint Pharmaceuticals, Inc.
03/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD - Significant investigator and patient interest drove strong recruitment, exceeding enrollment goals - Topline DAVIO 2 data anticipated in Q4 2023 WATERTOWN, Mass., March 27, 2023 – EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it has completed enrollment in the Phase 2 "Durasert® and Vorolanib in Ophthalmology 2" clinical trial evaluating EYP-1901 as a potential six-month maintenance treatment for wet age-related macular degeneration . The trial exceeded its original target of 144 patients, enrolling a total of..."
03/10/2023 8-K Other Events  Interactive Data
03/10/2023 10-K Annual Report for the period ended December 31, 2022
03/02/2023 8-K Quarterly results
Docs: "EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments – Phase 2 DAVIO 2 clinical trial in wet AMD on track with topline data anticipated by year-end 2023 – – Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopathy on track with enrollment completion anticipated in 4Q 2023 – – Net product revenues for Full Year 2022 of $39.9 million, a 13.0% increase versus Full Year 2021 of $35.3 million – – $144.6M of cash and investments at December 31, 2022 with cash runway projected into 2H 2024 – – Management to host a conference call and webcast today at 8:30 a.m. ET – WATERTOWN, Mass., March 2, 2023 – EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve..."
02/13/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/13/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/13/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/13/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/13/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/13/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/13/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy